Kamenosono Takeshi | Shin Nippon Biomedical Laboratories Ltd. Drug Safety Research Laboratories
スポンサーリンク
概要
- Kamenosono Takeshiの詳細を見る
- 同名の論文著者
- Shin Nippon Biomedical Laboratories Ltd. Drug Safety Research Laboratoriesの論文著者
関連著者
-
Nagata Ryoichi
Shin Nippon Biomedical Laboratories (snbl) Ltd.
-
Nagata Ryoichi
Shin Nippon Biomedical Laboratories Ltd.
-
Kamenosono Takeshi
Shin Nippon Biomedical Laboratories, Ltd., Drug Safety Research Laboratories
-
Kamenosono Takeshi
Shin Nippon Biomedical Laboratories Ltd. Drug Safety Research Laboratories
-
Nagata Ryoichi
Toxicology Division Shin Nippon Biomedical Laboratories
-
Fukuzaki Koichiro
Shin Nippon Biomedical Laboratories Ltd. Drug Safety Research Laboratories
-
Fukuzaki Koichiro
Shin Nippon Biomedical Laboratories (snbl) Ltd.
-
Fukuzaki Koichirou
Snbl Usa Ltd.
-
Nagata Ryoichi
Shin Nippon Biomedical Lab. Ltd.
-
NAGATA Ryoichi
Shin Nippon Biomedical Laboratories (SNBL), Ltd.
著作論文
- Characteristics of troponins as myocardial damage biomarkers in cynomolgus monkeys
- Validation and Application of Enzyme Linked Immuno-Sorbent Assays (ELISAs) for Quantification of Toxicology Parameters in Cynomolgus Monkey (TEST METHODS) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)
- Quantitation of Dopamine, 3,4-Dihydroxyphenylacetic Acid and Homovanillic Acid in MPTP-Treated Marmosets Using a Validated Analytical HPLC Method with Electrochemical Detection (NEREVOUS SYSTEM) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the
- 21B-11-4 Physiological and Pharmacological Studies in Cynomolgus Monkeys using Telemetry System (III), Applications of Conscious Monkeys to Safety Pharmacology Studies.
- 21B-11-3 Physiological and pharmacological Studies in Cynomolgus Monkeys using Telemetry System (II), The Circadian Rhythm of Cardiovascular Hemodynamics in Normotensive and Hypertensive Monkeys.
- P-1 Circadian rhythm of circulating active substances in conscious monkeys using an automatic blood sampling method(Proceedings of the 27th Annual Meeting)
- O-39 Strategy for preclinical evaluation of the proarrhythmic risk.(Proceedings of the 27th Annual Meeting)